Results 171 to 180 of about 184,097 (304)

Metabolic syndrome and venous thromboembolism: the role of abdominal obesity and sex differences. [PDF]

J Thromb Thrombolysis
Brodin N, Nymberg P, Bolmsjö BB, Svensson PJ, Elf J, Zöller B, Calling S.   +6 more
europepmc   +1 more source

Olfactory Dysfunction and Metabolic Syndrome Components: A Systematic Review and Meta‐Analysis

The Laryngoscope, EarlyView.
ABSTRACT Objective To elucidate the association between olfactory dysfunction (OD) and metabolic syndrome components. Data Sources PubMed (National Library of Medicine—National Institutes of Health), Scopus (Elsevier), CINAHL Complete (EBSCOhost), and the Cochrane Library (Wiley) databases were searched from inception through March 23rd, 2026.
Neeti Gandra, Kaitlyn A. Roberts, Shaun A. Nguyen, Pete Peters, Lauren A. Howser, Zachary M. Soler, Rodney J. Schlosser   +6 more
wiley   +1 more source

Emotional Eating and Abdominal Obesity: A Narrative Review of the Potential Mechanisms Underlying Their Relationship and Emerging Interventions for Their Management. [PDF]

Nutrients
Guillén-Medina LY, Rodriguez-Rocha NP, Altamirano-Martínez MB, Maldonado-Ulloa G, Mora-López GV, Macedo-Ojeda G.   +5 more
europepmc   +1 more source

How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Pelvic organ prolapse is a common condition and many women seek surgical treatment for prolapse symptoms. However, recurrence of prolapse after surgical treatment is common. A think tank was held at ICI‐RS 2025 to discuss how the assessment and indifferent results from conservative and surgical management can be improved.
Rohna Kearney, Adrian Wagg, Wendy Bower, Chris Chapple, Vik Khullar, Dudley Robinson, Annika Taithongchai, Philip Toozs Hobson, Alan Wein, Paul Abrams   +9 more
wiley   +1 more source

Dynapenic Abdominal Obesity and the Risk of Non-Neoplastic Digestive System Diseases in Postmenopausal Women: A Prospective Cohort Study. [PDF]

Int J Womens Health
Dong X, Zhang Y, Zhang C, Huang G, Liu Y, Li M.   +5 more
europepmc   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Associations of abdominal obesity and plasma fatty acids with microvascular diseases. [PDF]

Commun Med (Lond)
Shi R, Yu L, Liu S, Sun G, Zhang D, Li X, Zhang Q, Xing X, Zhang X, Yang X.   +9 more
europepmc   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

Waist-to-Height Ratio and the Risk of Cardiovascular Outcomes and Mortality in Type 2 Diabetes With and Without Abdominal Obesity. [PDF]

Diabetes Obes Metab
Park KY, Han K, Park JH, Lee CB, Park HK, Hwang HS, Hong S, Yu SH.   +7 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source